RenovoRx Inc
RNXT
Company Profile
Business description
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Contact
2570 West El Camino Real
Suite 320
Mountain ViewCA94040
USAT: +1 650 284-4433
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
17
Stocks News & Analysis
stocks
AMD: We’re pleased with Anthropic Partnership ahead of advancing AI event
We’re encouraged that AMD will count Anthropic as a third leading AI customer, in addition to OpenAI and Meta.
stocks
The most popular ASX trades in FY26
A closer look at the stocks and ETFs that captured Aussie investors’ attention in FY26.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,018.10 | 41.40 | -0.46% |
| CAC 40 | 8,374.12 | 63.77 | -0.76% |
| DAX 40 | 25,069.45 | 85.96 | -0.34% |
| Dow JONES (US) | 52,218.58 | 6.06 | -0.01% |
| FTSE 100 | 10,717.44 | 0.47 | 0.00% |
| HKSE | 25,210.81 | 318.15 | 1.28% |
| NASDAQ | 25,690.90 | 146.30 | -0.57% |
| Nikkei 225 | 66,422.60 | 307.00 | 0.46% |
| NZX 50 Index | 13,795.31 | 32.13 | 0.23% |
| S&P 500 | 7,498.96 | 10.24 | -0.14% |
| S&P/ASX 200 | 8,839.00 | 38.60 | -0.43% |
| SSE Composite Index | 3,876.78 | 9.74 | 0.25% |